Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin

por Kühnast, Susan, van der Hoorn, José W. A., Pieterman, Elsbet J., van den Hoek, Anita M., Sasiela, William J., Gusarova, Viktoria, Peyman, Anusch, Schäfer, Hans-Ludwig, Schwahn, Uwe, Jukema, J. Wouter, Princen, Hans M. G.
Publicado 2014

Niacin Reduces Atherosclerosis Development in APOE*3Leiden.CETP Mice Mainly by Reducing NonHDL-Cholesterol

por Kühnast, Susan, Louwe, Mieke C., Heemskerk, Mattijs M., Pieterman, Elsbet J., van Klinken, Jan B., van den Berg, Sjoerd A. A., Smit, Johannes W. A., Havekes, Louis M., Rensen, Patrick C. N., van der Hoorn, José W. A., Princen, Hans M. G., Jukema, J. Wouter
Publicado 2013

Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin

por Kühnast, Susan, van der Tuin, Sam J.L., van der Hoorn, José W.A., van Klinken, Jan B., Simic, Branko, Pieterman, Elsbet, Havekes, Louis M., Landmesser, Ulf, Lüscher, Thomas F., Willems van Dijk, Ko, Rensen, Patrick C.N., Jukema, J. Wouter, Princen, Hans M.G.
Publicado 2015